Therefore, on the basis of these laboratory parameters indicative of severe inflammation and the tumor mutational profile positive for PIK3CA gene mutation, in October, we decided to initiate therapy with the selective inhibitor Janus-Associated Kinases (JAKs) JAK1 and JAK2, ruxolitinib (JAKAVI©), at 10 mg/day, and the oral selective inhibitor of the phosphoinositol-3-kinase (PIK3), alpesilib (PIQRAY©), at 300 mg/day. This evidence concerns the gene PIK3CA and neoplasm.